Terkko Navigator / Lancet Oncology

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

Increased telomerase activity and comprehensive lifestyle changes: a pilot study.

Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies.

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

EUROCARE-4 studies bring new data on cancer survival.

Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study.

Electrical killing fields for cancer cells.

Death threats for discrepancies over treatment data.

New markers to detect prostate cancer.

New tumour suppressor linked to Wilms' tumour.

Part I: Spinal-cord neoplasms-intradural neoplasms.